Actively Recruiting
Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation
Led by Fundación IVI · Updated on 2025-02-27
60
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
Sponsors
F
Fundación IVI
Lead Sponsor
I
Instituto Valenciano de Infertilidad, IVI VALENCIA
Collaborating Sponsor
AI-Summary
What this Trial Is About
Both controlled ovarian stimulation (COS) and frozen embryo transfer has become an integral part of in vitro fertilization (IVF) treatment. Fresh embryo transfer is usually performed by providing Luteal Phase Support (LPS) with progesterone after COS. Frozen embryo transfer (FET) is usually performed in artificial cycles with hormone replacement treatment (HRT), in which exogenous progesterone is administered, although it can also be performed in a Natural Cycle (without hormone supplementation) (NC). There is evidence that the supraphysiologic levels of estradiol and progesterone during COS+LPS and HRT could lead to morphologic and biochemical endometrial modifications, altering endometrial receptivity and lowering implantation and pregnancy rates. We hypothesize that the supraphysiologic hormone levels required for both COS+LPS, and HRT may be inducing alterations in endometrial composition and function, specifically the chronic accumulation of senescent cells; either due to an excessive hormonal induction, a lack of clearance due to a deficit of uNKs, or a combination of both, ultimately affecting both endometrial receptivity and decidualization, worsening IVF outcomes. The in vitro clearance of endometrial senescent cells by selective induction of apoptosis has been found to enhance the decidualization capacity of the rest of Endometrial Stromal Cells (EnSC), which could represent in a future adjuvant strategy to reduce the potentially deleterious effects of supraphysiologic hormone levels and improve reproductive outcomes in IVF patients. The results derived from this project would have a direct impact on clinical practice. First, the results would allow us to evaluate, based on experimental data, potential endometrial side effects of stimulation protocols commonly used in IVF treatments. In addition, in the case of finding a pathological accumulation of senescent cells affecting endometrial receptivity, we will be able to in vitro evaluate the effectiveness of adjuvant senolytic (drugs designed to specifically remove senescent cells) compounds to in vitro improve the expression of endometrial receptivity markers, as a first step to demonstrate the effectiveness of their use in improving the reproductive outcomes of IVF patients.
CONDITIONS
Official Title
Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 45 years
- Body mass index (BMI) between 18.5 and 30
- Women aged 18 to 35 years (for endometrial receptivity reference group)
- BMI between 18.5 and 25 (for endometrial receptivity reference group)
You will not qualify if you...
- Any uterine disease affecting the endometrial cavity
- Thin or irregular endometrium
- Altered karyotypes
- Blood clotting disorders (thrombophilias)
- Uncorrected systemic or endocrine diseases
- Presence of intrauterine device (IUD) in the last three months (for reference group)
- Use of hormonal contraceptives in the last three months (for reference group)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IVI-RMA Valencia Clinic
Valencia, Spain, 46015
Actively Recruiting
Research Team
F
Francisco Domínguez Hernández, PhD
CONTACT
R
Roberto González Martín, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here